Edgar Filing: GREATHOUSE KENNETH - Form 4

Form 4 June 01, 20)18								
FOR	M 4							APPROVAL	
	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549						OMB Number:	3235-0287	
	this box	Washington, D.C. 20349					Expires:	January 31,	
if no lo subject Section Form 4	MENT OF	F CHAN	NGES IN BENEH SECURITIES	ICIAL O	WNERSHIP OF	Estimated burden ho response.	ours per		
Form 5 obligati may co <i>See</i> Ins 1(b).	ions Section 17	(a) of the F	Public U	16(a) of the Secur Jtility Holding Co nvestment Compa	mpany Act	of 1935 or Sectio			
(Print or Type	e Responses)								
GREATHOUSE KENNETH Syn			2. Issuer Name and Ticker or Trading Symbol			5. Relationship of Reporting Person(s) to Issuer			
		Zosano Pharma Corp [ZSAN]				(Check all applicable)			
(Last) (First) (Middle) C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT			3. Date of Earliest Transaction (Month/Day/Year) 05/31/2018			X_ Director 10% Owner Officer (give title below) Other (specify below)			
FREMON	(Street) T, CA 94555			endment, Date Origin onth/Day/Year)	al	6. Individual or Jo Applicable Line) _X_ Form filed by 0 Form filed by N Person	One Reporting I	Person	
(City)	(State)	(Zip)	Tab	ole I - Non-Derivative	Securities A	Acquired, Disposed of	f, or Beneficia	ally Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	 3. 4. Securi TransactionAcquired Code Disposed (Instr. 8) (Instr. 3, Code V Amount 	(A) or of (D)	Securities H Beneficially (Owned (Following (Reported Transaction(s) (Instr. 3 and 4)	5. Ownership Form: Direct D) or Indirect I) Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Re	eport on a separate line	e for each cla	ass of sec	urities beneficially ow	ned directly	or indirectly.			
				infor requi	nation cont red to resp ays a curre	spond to the collec tained in this form ond unless the for ntly valid OMB con	are not m	SEC 1474 (9-02)	
	Tab			curities Acquired, Di ls, warrants, options,					
1. Title of		saction Date			5. Number iorDerivative			7. Title and Amount of Underlying Securities	

Edgar Filing: GREATHOUSE KENNETH - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/Year)		(Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 4.24	05/31/2018 <u>(1)</u>		А	25,000	<u>(2)</u>	04/16/2028	Common Stock	25,000
Reporting Owners									

Reporting Owner Name / Address		Relationsh		
1	Director	10% Owner	Officer	Other
GREATHOUSE KENNETH C/O ZOSANO PHARMA CORPORATION 34790 ARDENTECH COURT FREMONT, CA 94555	X			
Signatures				
/s/ Jeffrey L. Quillen, attorney-in-fact	06/01/2018			
**Signature of Reporting Person	Date			

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The option grant was approved by the compensation committee of the Company's board of directors on April 16, 2018, subject to(1) stockholder approval of an amendment to the stock option plan under which the option was granted. The Company's stockholders approved the plan amendment on May 31, 2018.
- (2) The shares underlying the stock option vest in equal monthly installments over a four-year period, beginning on May 16, 2018, so that all shares shall have vested on April 16, 2022.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

C